Renal effects of imidazole-2-hydroxybenzoate in patients with compensated liver cirrhosis.
Int J Clin Pharmacol Ther Toxicol
; 30(7): 225-9, 1992 Jul.
Article
in En
| MEDLINE
| ID: mdl-1506125
ABSTRACT
A double-blind crossover study versus placebo of the renal effects of the nonsteroidal anti-inflammatory drug imidazole 2-hydroxybenzoate was conducted in 10 patients with compensated liver cirrhosis. The administration of the drug (750 mg, t.i.d., for three days) did not affect renal plasma flow, glomerular filtration rate, free water clearance nor the urinary excretion of sodium or potassium. Values of plasma renin activity also did not change after drug administration. Direct tubular damage from imidazole 2-hydroxybenzoate was also excluded by normal excretion of beta-2-microglobulin and N-acetyl-beta-D-glucosaminidase. Urinary 6-keto-PGF1 alpha output were comparable during imidazole 2-hydroxybenzoate and placebo administration. These data indicate that this nonsteroidal antiinflammatory drug does not affect the renal function in patients with compensated liver cirrhosis.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Salicylates
/
Anti-Inflammatory Agents, Non-Steroidal
/
Imidazoles
/
Kidney
/
Liver Cirrhosis
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Int J Clin Pharmacol Ther Toxicol
Year:
1992
Document type:
Article
Affiliation country:
Italy